Medigen Vaccine Biologics Corporation

6547

TW0006547003

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-06-25 pm EDT			5-day change	1st Jan Change
52.7 ^TWD	+1.74%		+0.76%	-24.82%

Jun. 13	Medigen Vaccine Biologics Corporation Announces General Manager	CI
Jun. 13	Medigen Vaccine Biologics Corporation Announces Audit Committee and Remuneration Committee Member Changes	CI

Medigen Vaccine Biologics Corporation Announces Audit Committee and Remuneration Committee Member Changes

June 13, 2024 at 06:16 am EDT

Medigen Vaccine Biologics Corporation announced appointment of Peng-Fei, Su as member of Audit Committee and Remuneration Committee in place of Chia-Hsiu, Lin. Resume of Peng-Fei, Su: Senior Vice-President of Shengye Assets Co.,Ltd. Effective date of the new member: JUNE 13, 2024.

Latest news about Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation Announces General Manager	Jun. 13	CI
Medigen Vaccine Biologics Corporation Announces Audit Committee and Remuneration Committee Member Changes	Jun. 13	CI
Medigen Vaccine Biologics Corporation Announces Directorate Changes	Jun. 13	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Medigen Vaccine Biologics Corporation Provides License Covid-19 Vaccine to WHO C-TAP and UN Medicines Patent Pool	23-08-29	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review	23-07-21	CI
Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees	23-06-29	CI
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine to Drug Administration of Vietnam	23-05-24	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Medigen Vaccine Biologics Corporation Announces Board Changes	23-03-08	CI
Medigen Vaccine Biologics Corporation Announces the Resignation of Chang, Ming-Cheng as Independent Director	23-03-08	CI
Medigen Vaccine Biologics Corporation Receives the NDA Approval Letter of Mvcquadrivalent Influenza Vaccine from Taiwan Food and Drug Administration	23-03-08	CI
Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand	22-12-05	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Taiwan's Medigen Vaccine Seeks Regulatory Approval for COVID Vaccine in Australia	22-06-07	MT
MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration	22-06-06	CI
Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine	22-05-13	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Taiwan approves second COVID booster dose, infections yet to peak	22-04-21	RE
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI

Chart Medigen Vaccine Biologics Corporation

Duration

Period

Chart Medigen Vaccine Biologics Corporation

More charts

Company Profile

Medigen Vaccine Biologics Corp is a Taiwan-based company principally engaged in the development and manufacture of vaccines and biological agents. The Company is engaged in the research, design, development, manufacture, and sale of cell culture vaccines such as influenza vaccines, enterovirus vaccines and dengue vaccines, as well as other biological agents. The main products include enterovirus 71 vaccines (Envacgen), quadrivalent seasonal influenza vaccines, and coronavirus disease 2019 (COVID-19) vaccines. The Company primarily distributes products in Taiwan.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MEDIGEN VACCINE BIOLOGICS CORPORATION	-24.82%	531M
CSL LIMITED	+2.97%	94.74B
SAMSUNG BIOLOGICS CO.,LTD.	-4.08%	37.28B
BIOGEN INC.	-11.87%	32.68B
UCB	+74.97%	27.72B
BIOMARIN PHARMACEUTICAL INC.	-13.38%	16.19B
INCYTE CORPORATION	-2.42%	13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.67%	11.58B
ALTEOGEN INC.	+190.36%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-52.61%	9.54B

Biopharmaceuticals